Congenital Hyperinsulinism Market, Global Outlook and Forecast 2022-2028

January 2022 | 60 pages | ID: C22C0ABEC2D8EN
Market Monitor Global

Abstracts

Congenital hyperinsulinism (CHI) is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.

This report contains market size and forecasts of Congenital Hyperinsulinism in Global, including the following market information:

Global Congenital Hyperinsulinism Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Congenital Hyperinsulinism market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Surgery Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Congenital Hyperinsulinism include IVAX Pharmaceuticals, Teva Pharmaceuticals, Zealand Pharma, Rezolute, Xeris Pharmaceuticals, Eiger BioPharmaceuticals, AmideBio and Recordati, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Congenital Hyperinsulinism companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Congenital Hyperinsulinism Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Congenital Hyperinsulinism Market Segment Percentages, by Type, 2021 (%)

• Surgery
• Medication
• Others

Global Congenital Hyperinsulinism Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Congenital Hyperinsulinism Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Congenital Hyperinsulinism Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Congenital Hyperinsulinism Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Congenital Hyperinsulinism revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Congenital Hyperinsulinism revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• IVAX Pharmaceuticals
• Teva Pharmaceuticals
• Zealand Pharma
• Rezolute
• Xeris Pharmaceuticals
• Eiger BioPharmaceuticals
• AmideBio
• Recordati

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Congenital Hyperinsulinism Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Congenital Hyperinsulinism Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CONGENITAL HYPERINSULINISM OVERALL MARKET SIZE

2.1 Global Congenital Hyperinsulinism Market Size: 2021 VS 2028
2.2 Global Congenital Hyperinsulinism Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Congenital Hyperinsulinism Players in Global Market
3.2 Top Global Congenital Hyperinsulinism Companies Ranked by Revenue
3.3 Global Congenital Hyperinsulinism Revenue by Companies
3.4 Top 3 and Top 5 Congenital Hyperinsulinism Companies in Global Market, by Revenue in 2021
3.5 Global Companies Congenital Hyperinsulinism Product Type
3.6 Tier 1, Tier 2 and Tier 3 Congenital Hyperinsulinism Players in Global Market
  3.6.1 List of Global Tier 1 Congenital Hyperinsulinism Companies
  3.6.2 List of Global Tier 2 and Tier 3 Congenital Hyperinsulinism Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Congenital Hyperinsulinism Market Size Markets, 2021 & 2028
  4.1.2 Surgery
  4.1.3 Medication
  4.1.4 Others
4.2 By Type - Global Congenital Hyperinsulinism Revenue & Forecasts
  4.2.1 By Type - Global Congenital Hyperinsulinism Revenue, 2017-2022
  4.2.2 By Type - Global Congenital Hyperinsulinism Revenue, 2023-2028
  4.2.3 By Type - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Congenital Hyperinsulinism Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Congenital Hyperinsulinism Revenue & Forecasts
  5.2.1 By Application - Global Congenital Hyperinsulinism Revenue, 2017-2022
  5.2.2 By Application - Global Congenital Hyperinsulinism Revenue, 2023-2028
  5.2.3 By Application - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Congenital Hyperinsulinism Market Size, 2021 & 2028
6.2 By Region - Global Congenital Hyperinsulinism Revenue & Forecasts
  6.2.1 By Region - Global Congenital Hyperinsulinism Revenue, 2017-2022
  6.2.2 By Region - Global Congenital Hyperinsulinism Revenue, 2023-2028
  6.2.3 By Region - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Congenital Hyperinsulinism Revenue, 2017-2028
  6.3.2 US Congenital Hyperinsulinism Market Size, 2017-2028
  6.3.3 Canada Congenital Hyperinsulinism Market Size, 2017-2028
  6.3.4 Mexico Congenital Hyperinsulinism Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Congenital Hyperinsulinism Revenue, 2017-2028
  6.4.2 Germany Congenital Hyperinsulinism Market Size, 2017-2028
  6.4.3 France Congenital Hyperinsulinism Market Size, 2017-2028
  6.4.4 U.K. Congenital Hyperinsulinism Market Size, 2017-2028
  6.4.5 Italy Congenital Hyperinsulinism Market Size, 2017-2028
  6.4.6 Russia Congenital Hyperinsulinism Market Size, 2017-2028
  6.4.7 Nordic Countries Congenital Hyperinsulinism Market Size, 2017-2028
  6.4.8 Benelux Congenital Hyperinsulinism Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Congenital Hyperinsulinism Revenue, 2017-2028
  6.5.2 China Congenital Hyperinsulinism Market Size, 2017-2028
  6.5.3 Japan Congenital Hyperinsulinism Market Size, 2017-2028
  6.5.4 South Korea Congenital Hyperinsulinism Market Size, 2017-2028
  6.5.5 Southeast Asia Congenital Hyperinsulinism Market Size, 2017-2028
  6.5.6 India Congenital Hyperinsulinism Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Congenital Hyperinsulinism Revenue, 2017-2028
  6.6.2 Brazil Congenital Hyperinsulinism Market Size, 2017-2028
  6.6.3 Argentina Congenital Hyperinsulinism Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Congenital Hyperinsulinism Revenue, 2017-2028
  6.7.2 Turkey Congenital Hyperinsulinism Market Size, 2017-2028
  6.7.3 Israel Congenital Hyperinsulinism Market Size, 2017-2028
  6.7.4 Saudi Arabia Congenital Hyperinsulinism Market Size, 2017-2028
  6.7.5 UAE Congenital Hyperinsulinism Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 IVAX Pharmaceuticals
  7.1.1 IVAX Pharmaceuticals Corporate Summary
  7.1.2 IVAX Pharmaceuticals Business Overview
  7.1.3 IVAX Pharmaceuticals Congenital Hyperinsulinism Major Product Offerings
  7.1.4 IVAX Pharmaceuticals Congenital Hyperinsulinism Revenue in Global Market (2017-2022)
  7.1.5 IVAX Pharmaceuticals Key News
7.2 Teva Pharmaceuticals
  7.2.1 Teva Pharmaceuticals Corporate Summary
  7.2.2 Teva Pharmaceuticals Business Overview
  7.2.3 Teva Pharmaceuticals Congenital Hyperinsulinism Major Product Offerings
  7.2.4 Teva Pharmaceuticals Congenital Hyperinsulinism Revenue in Global Market (2017-2022)
  7.2.5 Teva Pharmaceuticals Key News
7.3 Zealand Pharma
  7.3.1 Zealand Pharma Corporate Summary
  7.3.2 Zealand Pharma Business Overview
  7.3.3 Zealand Pharma Congenital Hyperinsulinism Major Product Offerings
  7.3.4 Zealand Pharma Congenital Hyperinsulinism Revenue in Global Market (2017-2022)
  7.3.5 Zealand Pharma Key News
7.4 Rezolute
  7.4.1 Rezolute Corporate Summary
  7.4.2 Rezolute Business Overview
  7.4.3 Rezolute Congenital Hyperinsulinism Major Product Offerings
  7.4.4 Rezolute Congenital Hyperinsulinism Revenue in Global Market (2017-2022)
  7.4.5 Rezolute Key News
7.5 Xeris Pharmaceuticals
  7.5.1 Xeris Pharmaceuticals Corporate Summary
  7.5.2 Xeris Pharmaceuticals Business Overview
  7.5.3 Xeris Pharmaceuticals Congenital Hyperinsulinism Major Product Offerings
  7.5.4 Xeris Pharmaceuticals Congenital Hyperinsulinism Revenue in Global Market (2017-2022)
  7.5.5 Xeris Pharmaceuticals Key News
7.6 Eiger BioPharmaceuticals
  7.6.1 Eiger BioPharmaceuticals Corporate Summary
  7.6.2 Eiger BioPharmaceuticals Business Overview
  7.6.3 Eiger BioPharmaceuticals Congenital Hyperinsulinism Major Product Offerings
  7.6.4 Eiger BioPharmaceuticals Congenital Hyperinsulinism Revenue in Global Market (2017-2022)
  7.6.5 Eiger BioPharmaceuticals Key News
7.7 AmideBio
  7.7.1 AmideBio Corporate Summary
  7.7.2 AmideBio Business Overview
  7.7.3 AmideBio Congenital Hyperinsulinism Major Product Offerings
  7.7.4 AmideBio Congenital Hyperinsulinism Revenue in Global Market (2017-2022)
  7.7.5 AmideBio Key News
7.8 Recordati
  7.8.1 Recordati Corporate Summary
  7.8.2 Recordati Business Overview
  7.8.3 Recordati Congenital Hyperinsulinism Major Product Offerings
  7.8.4 Recordati Congenital Hyperinsulinism Revenue in Global Market (2017-2022)
  7.8.5 Recordati Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Congenital Hyperinsulinism Market Opportunities & Trends in Global Market
Table 2. Congenital Hyperinsulinism Market Drivers in Global Market
Table 3. Congenital Hyperinsulinism Market Restraints in Global Market
Table 4. Key Players of Congenital Hyperinsulinism in Global Market
Table 5. Top Congenital Hyperinsulinism Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Congenital Hyperinsulinism Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Congenital Hyperinsulinism Revenue Share by Companies, 2017-2022
Table 8. Global Companies Congenital Hyperinsulinism Product Type
Table 9. List of Global Tier 1 Congenital Hyperinsulinism Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Congenital Hyperinsulinism Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Congenital Hyperinsulinism Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Congenital Hyperinsulinism Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Congenital Hyperinsulinism Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Congenital Hyperinsulinism Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Congenital Hyperinsulinism Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Congenital Hyperinsulinism Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Congenital Hyperinsulinism Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Congenital Hyperinsulinism Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Congenital Hyperinsulinism Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Congenital Hyperinsulinism Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Congenital Hyperinsulinism Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Congenital Hyperinsulinism Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Congenital Hyperinsulinism Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue, (US$, Mn), 2023-2028
Table 30. IVAX Pharmaceuticals Corporate Summary
Table 31. IVAX Pharmaceuticals Congenital Hyperinsulinism Product Offerings
Table 32. IVAX Pharmaceuticals Congenital Hyperinsulinism Revenue (US$, Mn), (2017-2022)
Table 33. Teva Pharmaceuticals Corporate Summary
Table 34. Teva Pharmaceuticals Congenital Hyperinsulinism Product Offerings
Table 35. Teva Pharmaceuticals Congenital Hyperinsulinism Revenue (US$, Mn), (2017-2022)
Table 36. Zealand Pharma Corporate Summary
Table 37. Zealand Pharma Congenital Hyperinsulinism Product Offerings
Table 38. Zealand Pharma Congenital Hyperinsulinism Revenue (US$, Mn), (2017-2022)
Table 39. Rezolute Corporate Summary
Table 40. Rezolute Congenital Hyperinsulinism Product Offerings
Table 41. Rezolute Congenital Hyperinsulinism Revenue (US$, Mn), (2017-2022)
Table 42. Xeris Pharmaceuticals Corporate Summary
Table 43. Xeris Pharmaceuticals Congenital Hyperinsulinism Product Offerings
Table 44. Xeris Pharmaceuticals Congenital Hyperinsulinism Revenue (US$, Mn), (2017-2022)
Table 45. Eiger BioPharmaceuticals Corporate Summary
Table 46. Eiger BioPharmaceuticals Congenital Hyperinsulinism Product Offerings
Table 47. Eiger BioPharmaceuticals Congenital Hyperinsulinism Revenue (US$, Mn), (2017-2022)
Table 48. AmideBio Corporate Summary
Table 49. AmideBio Congenital Hyperinsulinism Product Offerings
Table 50. AmideBio Congenital Hyperinsulinism Revenue (US$, Mn), (2017-2022)
Table 51. Recordati Corporate Summary
Table 52. Recordati Congenital Hyperinsulinism Product Offerings
Table 53. Recordati Congenital Hyperinsulinism Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Congenital Hyperinsulinism Segment by Type in 2021
Figure 2. Congenital Hyperinsulinism Segment by Application in 2021
Figure 3. Global Congenital Hyperinsulinism Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Congenital Hyperinsulinism Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Congenital Hyperinsulinism Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Congenital Hyperinsulinism Revenue in 2021
Figure 8. By Type - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028
Figure 9. By Application - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028
Figure 10. By Region - Global Congenital Hyperinsulinism Revenue Market Share, 2017-2028
Figure 11. By Country - North America Congenital Hyperinsulinism Revenue Market Share, 2017-2028
Figure 12. US Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Congenital Hyperinsulinism Revenue Market Share, 2017-2028
Figure 16. Germany Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 17. France Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Congenital Hyperinsulinism Revenue Market Share, 2017-2028
Figure 24. China Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 28. India Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Congenital Hyperinsulinism Revenue Market Share, 2017-2028
Figure 30. Brazil Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Congenital Hyperinsulinism Revenue Market Share, 2017-2028
Figure 33. Turkey Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Congenital Hyperinsulinism Revenue, (US$, Mn), 2017-2028
Figure 37. IVAX Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Teva Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Zealand Pharma Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Rezolute Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Xeris Pharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Eiger BioPharmaceuticals Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AmideBio Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Recordati Congenital Hyperinsulinism Revenue Year Over Year Growth (US$, Mn) & (2017-2022)